12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prophage vitespen: Preliminary Phase II data

Preliminary data from a single-arm, U.S. Phase II trial in 46 patients with newly diagnosed GMB showed that intradermal Prophage G-100 plus standard of care (SOC) radiation and temozolomide led to a median PFS of 17 months and a median OS of 23.3 months....

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >